P erivascular adipose tissue (PVAT) surrounds the majority of blood vessels, and there is a growing body of evidence that it can release factors which are vital in regulating vascular tone and therefore blood pressure and nutrient delivery. [1] [2] [3] The exact mechanisms by which PVAT releases these relaxant factors are still unclear, hindering our understanding of how PVAT modulates vascular resistance.
P erivascular adipose tissue (PVAT) surrounds the majority of blood vessels, and there is a growing body of evidence that it can release factors which are vital in regulating vascular tone and therefore blood pressure and nutrient delivery. [1] [2] [3] The exact mechanisms by which PVAT releases these relaxant factors are still unclear, hindering our understanding of how PVAT modulates vascular resistance.
Sympathetic nerve fibers are abundant within the vasculature and adipose tissue depots, and it is accepted widely that white adipose tissue (WAT) responds to catecholamines secreted from sympathetic nerve fibers. [4] [5] [6] Sympathetic denervation of epididymal and inguinal fat pads consisting of WAT in vivo will increase lipid deposits, 7, 8 indicating that sympathetic innervation of adipose tissues plays a vital role in lipolysis. The origins of these fibres have been extensively studied using viral transneuronal retrograde tract tracers, namely the pseudorabies virus and the H129 strain of the herpes simplex virus 1. [9] [10] [11] Injection of these tracers into mesenteric, inguinal, or epididymal fat pads in hamsters reveals that the sympathetic fibers supplying these fat deposits originate from the central nervous system, starting at the forebrain. However, it is unclear whether the nerves are innervating the adipocytes directly.
Functional studies of the role of sympathetic nerves in the PVAT anticontractile effect are conflicting. In conduit arteries, electrical field stimulation (EFS) of PVAT to activate sympathetic nerve fibers has effects dependent on location. 12 In the WAT of the superior mesentery, EFS induced an anticontractile effect, whereas in the brown adipose tissue of the aorta, EFS induced a procontractile PVAT effect, which suggests that PVAT function may vary with the phenotype of the adipocytes or size of the vessel. Conversely, previous studies have reported an EFS-induced procontractile effect in the WAT of the superior mesenteric artery 13 and mesenteric resistance arteries. 13 However, the latter study used a much greater voltage than all other studies and proposed that the procontractile effect of PVAT is because of the generation of superoxide anions. The effects of lower voltage stimulations in PVAT-intact mesenteric resistance arteries have not yet been characterized.
In addition, the mechanisms by which anticontractile factors are released from PVAT are not fully understood; however, evidence suggests that the activation of adipocyte β 3 -adrenoceptors may play an important role. As previously discussed, lipolysis can be stimulated in WAT by sympathetic stimulation, and this process is mediated via β 3 -adrenoceptors present on WAT.
14 β 3 -adrenoceptors are highly expressed in rodent adipocytes, but not the vasculature, 15, 16 and immunohistochemical studies have confirmed that β 3 -adrenoceptors are expressed in human PVAT. 17 CL-316,243, a β 3 -adrenoceptor agonist, is hypotensive in both rodents and dogs, 18 and electrophysiological studies demonstrate that the same agonist elicits PVAT-dependent hyperpolarizations of vascular smooth muscle cells. 19 The effects of inhibition of adipocyte β 3 -adrenoceptors on PVAT function and vessel tension have not yet been characterized.
Adiponectin has been identified as a PVAT-derived relaxing factor because the application of exogenous adiponectin to mouse mesenteric arteries constricted with NA (noradrenaline) mimics the PVAT anticontractile effect. 20 Furthermore, inhibition of adiponectin receptor-1 abolishes the NA-induced PVAT anticontractile effect. 20, 21 In adiponectin-deficient mice, the β 3 -adrenoceptor agonist CL-316,243 does not induce PVAT-dependent hyperpolarizations observed in control mice 19 ; therefore, it is reasonable to suggest that the stimulation of β 3 -adrenoceptors within PVAT will trigger the release of adiponectin, but this needs investigating.
It has been suggested that NA transporters may play a role in PVAT anticontractile functions. 22, 23 Inhibition of OCT3 (organic cation transporter 3) using corticosterone significantly reduced NA uptake into PVAT, resulting in a higher NA concentration in the surrounding solution and potentially stimulating a larger vascular smooth muscle cell contraction. 23 However, it remains to be confirmed whether OCT3 plays a functional role in the PVAT anticontractile effect by allowing PVAT to act as a reservoir for NA, therefore, preventing the NA from reaching vascular smooth muscle cells and eliciting contraction.
Therefore, the present studies were designed to examine sympathetic nerves within PVAT and determine whether they play a functional role. We tested the hypothesis that the stimulation of sympathetic nerves within PVAT caused the release of NA. We anticipate that NA will activate adipocyte β 3 -adrenoceptors, triggering the release of adiponectin. In addition, we hypothesize that some NA will be sequestered by OCT3 into adipocytes, thereby preventing the NA from reaching the vessel and eliciting contraction.
Materials and Methods

Animal Care and Ex Vivo Measurements
All animal procedures complied with the UK Animal (Scientific Procedures) Act 1986 and were performed in accordance with the appropriate Home Office project license. Male C57BL/6J (Envigo, United Kingdom) and Adipoq tm1Chan mice (Jackson Laboratories) were fed a normal chow diet until euthanized at 18 to 20 weeks old by CO 2 asphyxiation. Before euthanasia, mice were fasted overnight and blood pressure was recorded in conscious, restrained animals using the CODA tail-cuff blood pressure monitoring system (Kent Scientific). Immediately after euthanasia, mixed blood samples were taken by severing the thoracic aorta. Blood glucose concentration was measured immediately using an automatic blood glucose system. The mesenteric bed and epididymal fat pads were exposed and removed.
Wire Myography
Second-order mesenteric arterial segments (<250 μm) were dissected in ice-cold physiological salt solution (PSS) of the following composition (mmol/L): NaCl, 119; KCl, 4.7; MgSO 4 , 1.17; NaHCO 3 , 25; KH 2 PO 4 , 1.17; EDTA, 0.03; Glucose, 5.5, and CaCl 2 , 1.6. PVAT was removed from some segments, and left intact on the adjacent segments. A third arterial preparation was used where a clean artery was mounted, and a section of exogenous PVAT was suspended above the vessel ( Figure I in the online-only Data Supplement). Arteries were mounted on 40 μm diameter wires (Danish MyoTech, Denmark) and left to equilibrate for 30 minutes before normalizing in a standardized procedure. 24 Normalization uses vessel length and wall tension to set vessels at a standardized starting tension. Arteries are stretched in gradual increments using a micrometer, and the passive force is measured using a Powerlab chart recorder (ADInstruments, United Kingdom), allowing calculation of wall tension. Using the wall tension, the Powerlab normalization software (LabChart v7; ADInstruments) can determine the effective pressure after each incremental stretch from the Laplace equation. An exponential curve is fitted using the effective pressure versus the internal circumference of the vessel. Previous studies in the rat mesentery have indicated that the maximal active tension occurs at 90% of the internal circumference, which is stable at a transmural pressure of 100 mm Hg. 24 Therefore, the exponential curve is used to calculate internal circumference at an essential pressure of 100 mm Hg, and vessel circumference is set at 90% of this calculated value.
After normalization, vessels were left for a further 30-minute equilibration period at 37°C , and bubbled at 95% air/5% CO 2 to maintain a pH of 7.4. After equilibration, vessels were challenged with 60 mmol/L high K + PSS (composition in mmol/L: NaCl, 63.7; KCl, 60; MgSO 4 , 1.17; NaHCO 3 , 25; KH 2 PO 4 , 1.17; K 2 EDTA, 0.03; Glucose, 5.5 and CaCl 2 , 1.6) to establish a maximum contractile response and confirm that removal of PVAT does not cause vascular injury. Vessels with a response <0.3 mN/mm 2 were excluded. 25 Responses were continuously recorded using LabChart 7 (ADInstruments).
Electrical Field Stimulation
After challenge with high K + PSS, endothelial function was assessed using 30 μmol/L of NA followed by a cumulative concentration-response to Ach (acetylcholine; 1×10 −7 -3−10 −5 mol/L). As consistent with previous studies, vessels with <30% relaxation to Ach were discarded. 25 Two
Nonstandard Abbreviations and Acronyms To determine the role of the endothelium, EFS responses of vessels with and without endothelium were compared. Endothelium was removed by insertion of equine hair into the vessel lumen to gently remove endothelial cells. When preconstricted with NA and tested using Ach as described above, vessels with <20% relaxation to Ach were considered to be endothelium denuded, as consistent with previous studies. 25 
Pharmacological Assessment
Vessels with and without exogenous PVAT were stimulated with EFS, and then the exogenous PVAT was removed and incubated for 30 minutes with sodium channel inhibitor tetrodotoxin (1 μmol/L), catecholamine toxin 6-hydroxydopamine (6-OHDA, 2 μmol/L), or OCT3 inhibitor corticosterone (100 μmol/L), before resuspending the exogenous PVAT in the bath with its original −PVAT vessel. A combination of SR59230A (1 μmol/L) and corticosterone (100 μmol/L) was also used in exogenous PVAT experiments.
In protocols using both PVAT-denuded vessels and PVAT-intact vessels, after the first EFS stimulation, β 3 -adrenoceptor antagonist SR59230A (1 μmol/L), β 3 -adrenoceptor agonist CL-316,243 (10 μmol/L), or ABP (adiponectin-blocking peptide) for receptor 1 (3.5 μg/mL) was added to the bath and incubated for 30 or 45 minutes, before restimulating the vessels. A combination of ABP (3.5 μg/mL) and SR59230A (1 μmol/L) or CL-316,243 (10 μmol/L) was also used in PVAT-intact vessel experiments.
The role of superoxide anions was investigated by incubating a pair of ±PVAT vessels with the scavenger SODPEG (superoxide dismutase polyethylene glycol, 200 U/mL) for 2 hours after equilibration and normalization. As a control, a second pair of ±PVAT vessels were incubated alongside in PSS for 2 hours. After the 2-hour incubation, the EFS protocol was performed as normal.
The effects of globular adiponectin (5 μg/mL) were tested on only −PVAT vessels. Vessels were stimulated once and allowed to recover for 15 minutes before adding adiponectin. The adiponectin was incubated for 5 minutes before repeating the EFS protocol.
Sample numbers of 8 for each vessel preparation (−PVAT, +PVAT, and +exogenous PVAT) were used for all experiments, with the exception of exogenous adiponectin and ABP experiments, for which a n of 4 was used because of the expense of these compounds (summary of all pharmacological tools is given in Table I in the online-only Data Supplement).
Solution Transfer Studies
PVAT-denuded vessels were mounted and stimulated at 10 Hz for 4 s, followed by a 15-minute recovery period. In separate baths, sections of exogenous PVAT were suspended between the platinum electrodes and stimulated at 10 Hz for 4 s. The solution surrounding the stimulated PVAT was transferred to the PVAT-denuded vessels, and the vessels were stimulated for a second time.
A second set of solution transfer experiments were conducted where the exogenous PVAT was first incubated with SR59230A (1 μmol/L) for 30 minutes and were rinsed immediately before stimulation to prevent transferring the drug to the −PVAT vessels during the solution transfer.
Adiponectin Assay
To quantify the concentration of adiponectin release from PVAT on EFS, PVAT was harvested from the entire mesenteric bed and weighed. The PVAT was incubated in a reduced volume myograph bath (3 mL) for 30 minutes in PSS bubbled with 95% air/5% CO 2 to equilibrate, before refreshing the surrounding PSS and stimulating using EFS at 10 Hz for 4 s (20 V, pulse duration 0.2 ms). The surrounding supernatant was collected and stored at −80°C until required. To examine the role of β 3 -adrenoceptors in adiponectin secretion, in separate PVAT samples, the PVAT was pre-incubated with β 3 -adrenoceptor antagonist SR59230A (1 μmol/L) for 30 minutes, before conducting the protocol as normal.
The concentration of adiponectin in the surrounding supernatant was measured using an ELISA kit (Life Technologies Ltd, United Kingdom; cat no. KMP0041). The manufacturer protocol was followed and unmodified. A 1 in 100 dilution of the collected supernatant was used, and adiponectin concentration was determined through measurement of absorbance using a plate reader (BioTek, Northstar Scientific, United Kingdom) at 450 nm. To account for variation in the amount of PVAT collected from each mesenteric bed, concentration was calculated per 100 mg of PVAT.
Drug Preparations
NA (Sigma Aldrich, United Kingdom; cat no. A7257), Ach (Sigma Aldrich, cat no. A6625), SODPEG (Sigma Aldrich, cat no. S9549) SR59230A (Bio-Techne, United Kingdom; cat no. 1151), and CL-316,243 (Bio-Techne, cat no. 1499) were dissolved in PSS. The blocking peptide for adiponectin receptor-1 was obtained from Enzo Life Sciences (United Kingdom; cat no. ALX-151-045-C100), and recombinant mouse globular adiponectin was obtained from Generon (United Kingdom; cat no. cyt-432-50 μg). Tetrodotoxin (Bio-Techne, cat no. 1078) was prepared in a citrate buffer, 6-OHDA (Sigma Aldrich, cat no. H4381) was dissolved in water containing 0.1% of antioxidant sodium metabisulfite (Na 2 S 2 O 5 ), and corticosterone (Sigma Aldrich, cat no. 27840) was dissolved in 100% ethanol. Vehicle controls were performed alongside these experiments ( Figure  II in the online-only Data Supplement).
Immunohistochemistry
PVAT samples and positive control tissues (kidney or brain) were placed in 4% ice-cold paraformaldehyde for 1 hour and subsequently washed in 0.1 mol/L Tris-buffered saline. Tissue was then embedded in KP-CryoCompound (Klinipath BV, The Netherlands) and stored at −80°C, before serial sectioning at 12 μm using a Leica CM 3050 cryostat (Leica Microsystems, Germany). Heat-induced antigen retrieval was performed in a citrate buffer, followed by blocking of endogenous peroxidase activity using 3% hydrogen peroxide . Tissues were incubated with 10% goat serum at room temperature for 1 hour to reduce nonspecific antibody binding, in combination with Triton-X 100 (0.1%) to increase permeability. Samples were incubated with antibodies for dopamine β-hydroxylase (10 μg/mL; Abcam, United Kingdom; cat no. ab96615), β 3 -adrenoceptors (10 μg/mL; Abcam, Cambridge; cat no. ab59685), or OCT3 (10 μg/mL; Sigma Aldrich; cat no. AV44026) overnight at 4°C. Slides were incubated for 1 hour with a biotinylated goat anti-rabbit secondary antibody (2 μg/mL; Abcam; cat no. ab6720) at room temperature. Vectastain Avidin-Biotin Complex (Vector Laboratories, United Kingdom) followed by the addition of 3,3′-diaminobenzidine solution (Vector Laboratories) was used for detection of antibody binding. Negative controls were conducted in PVAT. These were incubated with Tris-buffered saline in place of the primary antibody, and incubation with the secondary antibody and detection methods were conducted as normal. Images were captured using a color camera (Leica DFC450; Leica Microsystems, Germany) mounted on a microscope (Leica DM5000; Leica Microsystems).
Statistical Analysis
Contractile responses were expressed as a percentage of the maximum contraction elicited with high K + PSS, as consistent with other studies. 21, 26 High K + PSS responses were no different between ±PVAT vessel groups, or before and after drug treatments. Data are shown as the mean±SEM. Normal distribution was confirmed using the Shapiro-Wilk normality test. Differences between the frequencyresponse curves of ±PVAT vessels were tested using a 2-way ANOVA, with a Bonferroni post hoc test. Before and after drug treatments within the same vessel types were compared using a repeatedmeasures ANOVA, again followed by a Bonferroni post hoc test. The effects of the solution transfer were tested using a paired t test, and the concentrations of adiponectin provided by ELISA were compared using an unpaired t test. Statistical tests were conducted using GraphPad Prism (v6; GraphPad Software).
Results
EFS of PVAT Triggers the Release of an Endothelium-Independent Anticontractile Factor
The effects of EFS were tested on mesenteric vessels with PVAT removed and PVAT left intact. On each stimulus, there was a frequency-dependent contraction (−PVAT, P<0.0001; 3 Hz, P<0.05; 10 Hz, P<0.01; 30 Hz, P<0.001; n=8), which was significantly reduced with the presence of PVAT ( Figure 1A ; P<0.001; n=8). Vessels were given 15 minutes recovery before the stimulus was repeated. After this recovery, the anticontractile effect was reproducible (P<0.001; n=8); therefore, electrical activation of nerves within PVAT does elicit a reproducible anticontractile effect. To demonstrate that this effect is not simply because of PVAT forming a barrier around the tissue, the EFS protocol was repeated in PVAT-denuded vessels with a section of exogenous PVAT suspended above the vessel, and again contractility was significantly reduced in the presence of PVAT ( Figure 1B ; P<0.0001; n=8).
To confirm that the anticontractile effect is not due to generation of reactive oxygen species within PVAT on EFS, ±PVAT vessels were incubated with superoxide scavenger SODPEG for 2 hours before stimulation. Incubation with the scavenger had no effect on the anticontractile effect ( Figure 1C ; P<0.0001; n=8), indicating that our EFS protocol is not damaging the PVAT.
Solution transfer studies were conducted by transferring the solution surrounding a stimulated section of exogenous PVAT to a PVAT-denuded vessel. The vessels were stimulated once before and after the solution transfer. Post-transfer, the contraction was significantly reduced ( Figure 1D ; P<0.01; n=8), therefore confirming that the exogenous PVAT must have released an anticontractile factor into its surrounding environment.
To determine the role of the endothelium in the PVAT anticontractile effect, the effects of EFS on endothelium-denuded vessels were tested. In the absence of endothelium, the PVAT anticontractile effect persisted ( Figure 1E ; P<0.0001; n=8), confirming that this effect to be endothelium independent.
The Anticontractile Effect of PVAT Is Dependent on Sympathetic Nerve Firing
The presence of sympathetic nerves was confirmed immunohistochemically in sections of mouse mesenteric PVAT using antibodies for the sympathetic nerve marker dopamine β-hydroxylase (n=5, Figure 2A ). To confirm that the anticontractile response of PVAT elicited by EFS is due to sympathetic nerve activity, tetrodotoxin and 6-OHDA were used. Exogenous PVAT was incubated with the voltage-gated sodium channel inhibitor tetrodotoxin, before resuspending above PVAT-denuded vessels and repeating the EFS protocol. Tetrodotoxin successfully abolished the PVAT anticontractile effect ( Figure 2D ; P<0.0001; n=8), confirming the effect to be neurally mediated. In a similar protocol, catecholamine toxin 6-OHDA was incubated with exogenous PVAT and again successfully abolished the anticontractile effect ( Figure 2E ; P<0.0001; n=8); therefore, the anticontractile effect is dependent on sympathetic nerve firing.
The Release of the Anticontractile Factor Is Mediated via β 3 -Adrenoceptors
The presence of β 3 -adrenoceptors on mouse mesenteric adipocytes was confirmed using immunohistochemistry (n=5, Figure 3A ). To determine if these adrenoceptors modulate vascular tone, specific β 3 -adrenoceptor agonist and antagonists were used.
After control responses to EFS, ±PVAT vessels were incubated with CL-316,243 (10 μmol/L) for 30 minutes ( Figure 3D ). The agonist significantly enhanced the PVAT anticontractile effect (P<0.01; n=8) and had no effect on −PVAT vessels (P>0.05; n=8).
The solution transfer experiment shown in Figure 1D was repeated using sections of exogenous PVAT pre-incubated with the β 3 -adrenoceptor antagonist SR59230A for 30 minutes. Post-transfer there was no longer a significant reduction in contraction ( Figure 4A ; P>0.05; n=8), therefore confirming that the release of the anticontractile factor into the surrounding environment must be dependent on β 3 -adrenoceptor activation. However, when the effects of the β 3 -adrenoceptor antagonist were tested in vessels with their PVAT left intact, there was only a partial inhibition of the anticontractile effect ( Figure 4B ; P<0.01; n=8), and the response of PVAT-intact vessels was still significantly lower than that of the PVATdenuded vessels (P<0.0001). There was no effect of the β 3 -adrenoceptor antagonist on PVAT-denuded vessels.
Reuptake of NA Into PVAT Contributes to the Anticontractile Effect
Immunohistochemistry was used to confirm the presence of OCT3 in mouse mesenteric PVAT (n=5, Figure 5A ). The functional role of OCT3 was determined by incubating sections of exogenous PVAT with the inhibitor corticosterone, before resuspending the PVAT above a PVAT-denuded vessel and repeating the stimulus. Similar to the β 3 -adrenoceptor antagonist, inhibition of OCT3 significantly reduced the anticontractile effect ( Figure 5D ; P<0.001; n=8), but again the PVAT remained overall anticontractile (P<0.001). However, a combination of inhibition of β 3 -adrenoceptors and OCT3 completely abolished the effect ( Figure 5E ; P<0.0001; n=8), suggesting that both of these transporters and receptors mediate the anticontractile functions of PVAT.
The Anticontractile Factor Released on β 3 -Adrenoceptor Activation May Be Adiponectin
The effects of globular adiponectin were tested on −PVAT vessels. −PVAT vessels were subjected to EFS and allowed 15 minutes to recover. After the recovery period, globular adiponectin was added and allowed to incubate for 5 minutes before repeating the stimulus. Globular adiponectin significantly reduced the contractile responses to EFS of PVAT-denuded vessels ( Figure 6A ; P<0.001; n=4).
After control responses, ±PVAT vessels were incubated with ABP for 45 minutes. After incubation, the anticontractile effect of PVAT was significantly reduced (Figure 6B ; P<0.01; n=4); however, the PVAT remained overall anticontractile (P<0.05). ABP had no effect on vessels with PVAT removed (P>0.05).
+PVAT vessels were subjected to a control EFS protocol, before incubating with either SR59230A (1 μmol/L) or CL-316,243 (10 μmol/L) for 30 minutes. After incubation, the EFS protocol was repeated for a second time, before performing a second incubation with SR59230A or CL-316,243, in combination with the ABP (5 μg/mL), before repeating the EFS protocol for a third time. SR59230A again significantly reduced the anticontractile effect alone (Figure 6C ; n=4; P<0.01). When used in combination with the ABP, there was no further reduction in the PVAT anticontractile effect (n=4; P>0.05). CL-316,243 again significantly enhanced the PVAT anticontractile effect alone (Figure 6D ; n=4; P<0.01), and this enhancement was abolished by ABP (n=4; P<0.01). However, the combination of CL-316,243 and ABP was no different ) and given 15 minutes to recover before being stimulated for a second time (−PVAT first stim vs +PVAT first stim, P<0.001***; −PVAT second stim vs +PVAT second stim, P<0.001+++; −PVAT first stim vs −PVAT second stim, P>0.05; +PVAT first stim vs +PVAT second stim, P>0.05; n=8). B, PVAT-denuded vessels were mounted with a section of exogenous PVAT suspended above the vessel, and the EFS protocol was conducted (P<0.0001****; n=8). C, ±PVAT vessels were incubated with SODPEG (superoxide dismutase polyethylene glycol) for 2 hours before stimulating with EFS (−PVAT vs +PVAT, P<0.0001****; −PVAT and SODPEG vs +PVAT and SODPEG, P<0.0001++++; −PVAT vs −PVAT and SODPEG, P>0.05; +PVAT vs +PVAT and SODPEG, P>0.05; n=8). D, PVAT-denuded vessels were stimulated at 10 Hz and left to recover for 15 minutes. In a separate bath, a section of exogenous PVAT was stimulated at 10 Hz. The solution surrounding the exogenous PVAT was transferred to the PVAT-denuded vessel, before repeating the 10 Hz stimulus (P<0.01**; n=8). E, PVAT vessels with and without endothelium were subjected to EFS (−PVAT +endo vs +PVAT +endo, P<0.0001****; −PVAT −endo vs +PVAT −endo, P<0.0001++++; −PVAT −endo vs −PVAT +endo, P>0.05; +PVAT −endo vs +PVAT +endo, P>0.05; n=8). Data shown are mean±SEM.
from +PVAT control responses, that is, there was no reduction to the starting anticontractile effect, suggesting that ABP may not overcome both basal β 3 -adrenoceptor activation and activation with the agonist.
To quantify the concentration of adiponectin secreted by PVAT on EFS, PVAT was collected from the entire mesentery and stimulated with EFS in the presence and absence of SR59230A, and the concentration was calculated per 100 mg of PVAT ( Figure 6E ). On stimulation at 10 Hz, control PVAT released ≈874.3±65.65 ng/mL of adiponectin into the surrounding supernatant (n=8). When pre-incubated with SR59230A, adiponectin secretion is significantly reduced to 378.7±90.4 ng/mL (P<0.001; n=8). The results indicate that adiponectin is the anticontractile factor released from mouse mesenteric PVAT on β 3 -adrenoceptor activation.
To further investigate the importance of adiponectin in PVAT function, the anticontractile effect was studied in adiponectin knockout (adipo −/− ) mice. When compared with control C57 mice, adipo −/− mice had similar body weights ( Figure 7A ; P>0.05; n=8 for both groups) and similar sized epididymal fat depots ( Figure 7B ; P>0.05; n=8 for both groups). Blood pressure was recorded in conscious restrained mice using the CODA tail-cuff system ( Figure 7C ). Both systolic and diastolic blood pressure were significantly elevated in adipo −/− when compared with C57 controls (P<0.01; n=8 for both groups). Immediately after euthanize, fasting blood glucose was measured using an automatic monitor, and blood glucose was significantly elevated in adipo −/− mice ( Figure 7D ; P<0.01; n=8). Wire myography was used to assess PVAT function ( Figure 7E ). ±PVAT vessels from adipo −/− mice were subjected to EFS, and there was no difference between ±PVAT vessels (P>0.05; n=8). After the first stimulus, vessels were incubated with CL-316,243 (10 μm) for 30 minutes before repeating the EFS protocol. CL-316,243 had no effect on vessel contractility (P>0.05; n=8). The presence of β 3 -adrenoceptors in adipo −/− PVAT was confirmed using immunohistochemistry (n=5).
Discussion
This study investigated the potential role for the sympathetic nervous system in controlling the anticontractile function of PVAT. The main findings of this study were (1) electrical activation of sympathetic nerves in PVAT stimulates the release of a transferable anticontractile factor, (2) the release of the anticontractile factor is dependent on β 3 -adrenoceptor activation, (3) the PVAT anticontractile effect is dependent on adiponectin, (4) adiponectin is essential for normal vascular function, and (5) PVAT acts as a reservoir for sympathetic nerve-derived NA via OCT3, thereby preventing the NA from reaching the blood vessel and causing contraction.
All previous studies have used sympathomimetic drugs to elicit an anticontractile effect 1, 3, 21, 27, 28 ; therefore, the aim of this study was to use EFS to directly activate the nerve fibers, triggering the release of catecholamines. Our EFS protocol successfully elicited an endothelium-independent PVAT anticontractile effect similar to that reported using sympathomimetics. PVAT-denuded vessels with a section of exogenous PVAT suspended above also exhibited a similar reduction in contractility, confirming that the anticontractile effect is not simply because of PVAT forming a barrier and insulating the vessel from the EFS. Furthermore, the solution transfer studies illustrate that on nerve activation, a transferable anticontractile factor must be released from the PVAT into its surroundings.
Previously, it has been shown that a high voltage stimulus induces the release of procontractile factors from PVAT. 13 This study used the superoxide scavenger SODPEG to reduce this procontractile effect, thereby confirming the effect to be because of the generation of superoxide anions. Generally, superoxide production is considered to be a result of oxidative stress and leads to vascular dysfunction. 29 Therefore, production of superoxide in PVAT seems likely to be a result of damage to PVAT caused by the high voltage. In this study, the Gao protocol was replicated, and SODPEG had no effect on contractility, indicating that our protocol is not damaging the PVAT.
This study has used dopamine β-hydroxylase to mark the presence of sympathetic nerves within the mesenteric PVAT. Perhaps a more commonly used marker for sympathetic nerves is tyrosine hydroxylase. However, it has been shown that inflammatory cells also contain tyrosine hydroxylase such as macrophages, 30 T cells, 31 and inflammatory cytokines. 32 Because there is an abundance of inflammatory cells within PVAT, 21, 33, 34 it was determined that dopamine β-hydroxylase would be more appropriate.
The most common method for determining whether an effect has a neural origin is the use of tetrodotoxin. Incubation of exogenous PVAT with tetrodotoxin provided a complete inhibition of the anticontractile effect, confirming that the anticontractile effect is indeed neurally mediated. Currently, there is no evidence of parasympathetic nerves within PVAT, and morphological studies found no evidence of cholinergic, vasoactive intestinal peptidergic, or nitrergic nerves, concluding that 97% to 98% of nerves running within WAT are noradrenergic. 35 The rest of the nerves present within PVAT are likely to be sensory nerves, 5, 36 which may play a role in sensing the products of lipolysis, and feeding back to the central nervous system to regulate lipolysis. We were able to confirm the presence of sympathetic nerves functionally using the catecholamine toxin 6-OHDA, which similarly to tetrodotoxin, completely inhibited the anticontractile effect of the exogenous PVAT, thereby confirming that the anticontractile effect is mediated via sympathetic nerve fibers. Furthermore, the anticontractile factor released on EFS is endothelium independent, and in vessels stimulated with exogenous NA, 21 the PVAT anticontractile effect is also endothelium independent. This suggests that the anticontractile factor released by EFS from sympathetic nerves is NA. One limitation of this study is the lack of information on the concentration of NA released by sympathetic nerves within PVAT into the extracellular space adjacent to adrenoceptors. This has not been possible because of the limited sensitivity of commercially available assays.
As consistent with previous studies, 15, 16, 37 we have confirmed the presence of β 3 -adrenoceptors within rodent mesenteric PVAT. For the first time, we have demonstrated a functional role for β 3 -adrenoceptors in the PVAT anticontractile effect, by significantly reducing the effect using the β 3 -adrenoceptor antagonist. Our solution transfer studies using PVAT incubated with the β 3 -adrenoceptor antagonist confirm that the release of the anticontractile factor on electrical activation of sympathetic nerves is dependent on β 3 -adrenoceptor activation. However, the partial inhibition of the anticontractile effect by the antagonist in vessels with PVAT intact reveals that the release of the anticontractile factor is only one side of the PVAT story.
Our study has for the first time confirmed the presence of OCT3 in the mouse mesenteric PVAT using immunohistochemistry. This is consistent with previous studies in rat illustrating the presence of OCT3 in aortic and mesenteric PVAT. 23 OCT3, previously known as the extraneuronal transporter, plays a predominant role in what was originally termed uptake 2 . 38 It plays a vital role in the transport of solutes such as NA into the peripheral tissues. It has previously been shown that an NA uptake system exists within PVAT which is mediated via OCT3 23 ; however, our study is the first to demonstrate that inhibition of OCT3 in exogenous PVAT exhibits a significant increase in vessel tension, revealing that the anticontractile role of PVAT is in part to act as a reservoir for excess NA, preventing the NA from reaching the vessel and eliciting contraction.
This study has indicated that adiponectin is the anticontractile factor which is released by the activation of adipocyte β 3 -adrenoceptors, as secretion of adiponectin from PVAT was significantly reduced in the presence of the β 3 -adrenoceptor antagonist. In addition, application of exogenous adiponectin to PVAT-denuded vessels induced relaxation, and inhibition of adiponectin receptor-1 significantly increased contractile responses in +PVAT vessels. Moreover, the ABP reduced the enhancement of the anticontractile effect induced using the β 3 -adrenoceptor agonist and caused no further reduction in the anticontractile effect when used in combination with the β 3 -adrenoceptor antagonist. These results are consistent with other studies, which have reported an effect of ABP on responses to NA. 20, 21 Most importantly, the EFS-induced anticontractile effect is absent in the adipo −/− mouse, which is consistent with previous studies using NA as the vasoconstrictor. 28 However, there is evidence that the PVAT-derived anticontractile factor may be agonist dependent, as when vessels from adipo −/− mice are stimulated with serotonin, the anticontractile effect is still present. 28 Furthermore, we have previously reported that the addition of ABP to rat vessels challenged with the serotonin does not have the same antagonistic effect as in vessels constricted with NA. 39 This is the first study to report a hypertensive and hyperglycemic phenotype in adipo −/− mice. Similarly in adiponectin receptor-1 knockout mice, glucose clearance is reduced. 40 These results indicate that adiponectin is essential for normal blood pressure and glucose clearance; therefore, in human obesity, where adiponectin bioavailability is reduced 41 and PVAT function is lost, 42 these dysfunctions may be contributing to the development of metabolic syndrome.
In summary, the sympathetic nervous system in PVAT stimulates an anticontractile effect which has vital effects on vascular tone and therefore blood pressure and nutrient delivery. The sympathetic nerves release NA, which activates adipocyte β 3 -adrenoceptors, triggering the release of an anticontractile factor into the surrounding environment. Excess NA is transported into the PVAT via OCT3, preventing the NA from reaching the vessel and increasing contraction. We anticipate that in obesity, where autonomic dysfunction is known to occur, the sympathetic nerves in PVAT may become pathologically overactive, leading to a loss of PVAT anticontractile function. Loss of the neurally mediated PVAT anticontractile effect in obesity may contribute to the the development of hypertension and type-II diabetes mellitus in obese patients.
